Welcome to our dedicated page for Hoth Therapeutics SEC filings (Ticker: HOTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hoth Therapeutics, Inc. (HOTH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biopharmaceutical company, Hoth uses forms such as 10-K, 10-Q, 8-K, and registration statements to report on its business, financial condition, and material events.
In its Form 8-K filings, Hoth has reported items such as corporate presentations, employment agreements with key executives, patent-related developments for HT-001, and listing-compliance matters with The Nasdaq Capital Market. These current reports can give investors insight into topics like executive compensation arrangements, intellectual property strategy, and communications the company uses in discussions with investors.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically include detailed descriptions of Hoth’s pipeline programs, risk factors, research and development expenses, and other information relevant to its operations as a clinical-stage biopharmaceutical company. For Hoth, this may encompass narrative and disclosures related to HT-001, HT-KIT, HT-ALZ, its GDNF-based metabolic program, and other assets described in its public communications.
Stock Titan enhances access to these filings with AI-powered summaries that are designed to highlight key points from lengthy documents, such as major pipeline updates, regulatory milestones, or changes in capital structure. Users can review real-time updates as new filings are posted to EDGAR, explore Form 4 insider transaction reports when filed, and quickly navigate to sections that discuss clinical development, intellectual property, and corporate governance.
By using this page, investors and researchers can examine HOTH’s SEC filings alongside AI-generated explanations that aim to clarify complex language and help identify significant disclosures without replacing the need to read the original documents.
Hoth Therapeutics, Inc. entered into a securities purchase agreement to sell 2,857,144 shares of common stock at $0.70 per share, raising approximately $2.0 million in a registered direct offering under its Form S-3 shelf.
In a concurrent private placement, the company issued unregistered warrants to purchase up to 2,857,144 additional shares at $0.85 per share, exercisable six months after issuance for five years and subject to a 4.99% beneficial ownership cap, waivable up to 9.99% with 61 days’ notice. H.C. Wainwright & Co. acted as placement agent, earning cash fees and warrants to buy 142,857 shares at $0.875 per share. Hoth plans to use net proceeds for working capital and general corporate purposes and has suspended use of its existing at-the-market prospectus supplement, with no ATM sales until a new supplement is filed.
Hoth Therapeutics, Inc. is offering 2,857,144 shares of common stock at an offering price of $0.70 per share to several institutional investors pursuant to a securities purchase agreement dated April 1, 2026. The gross proceeds from the public portion of the offering are approximately $2.0 million, before placement agent fees and expenses.
The company is conducting a concurrent private placement of unregistered warrants to purchase up to 2,857,144 shares (one warrant per share sold) exercisable beginning six months from issuance for five years at an exercise price of $0.85 per share. Delivery of the shares is expected on or about April 2, 2026, subject to customary closing conditions.
Hoth Therapeutics is a clinical-stage biopharmaceutical company developing multiple programs for cancer-related skin toxicity (HT-001), mast-cell cancers and anaphylaxis (HT-KIT), Alzheimer’s and neuroinflammatory disease (HT-ALZ), eczema (BioLexa), asthma and allergies (HT-004), and obesity (HT-VA). HT-001 is in a Phase 2a trial with FDA and EMA approvals and positive interim open-label results, while HT-KIT holds U.S. orphan drug designation and is in IND-enabling studies. Other assets remain preclinical.
The company has no product revenue, reported net losses of $12.5 million in 2025 and $8.2 million in 2024, and an accumulated deficit of $72.9 million as of December 31, 2025. Its auditor expressed substantial doubt about its ability to continue as a going concern, and management discloses a need for substantial additional capital, with potential dilution or unfavorable partnering. Extensive regulatory, clinical, manufacturing and reimbursement risks, along with reliance on third-party contractors and intense industry competition, add further uncertainty.
Hoth Therapeutics, Inc. filed a Form 8-K to inform the market that it has prepared new presentation materials that management plans to use on and after January 16, 2026. These materials are intended for meetings with U.S. government officials focused on the company’s weight loss drug and broader therapeutics pipeline.
The presentation materials are provided as Exhibit 99.1. Hoth notes that the information in these materials is summary in nature and should be read together with its other SEC filings and public announcements. The company states that the materials speak as of the date of this Form 8-K and, while it may update them in the future, it specifically disclaims any obligation to do so.
Hoth Therapeutics, Inc. has filed a mixed shelf registration statement on Form S-3 covering the primary offering of up to $50 million of common stock, preferred stock, debt securities, warrants, subscription rights and units, plus the resale of up to 1,279,587 shares of common stock by a selling shareholder. The company can issue these securities from time to time using a base prospectus and detailed prospectus supplements that will set terms such as pricing, ranking and any conversion features. As of November 10, 2025, Hoth had 15,514,312 shares of common stock outstanding, and it qualifies as a smaller reporting company, which allows scaled disclosure. The filing explains Hoth’s clinical‑stage pipeline in oncology side‑effect management, mast‑cell cancers, anaphylaxis, Alzheimer’s and other indications, along with extensive risk factors related to funding needs, clinical development, regulation, digital assets holdings and Nasdaq listing.
Hoth Therapeutics amended its prospectus supplement to expand its at-the-market program with H.C. Wainwright. The company is now offering up to $4,821,200 of common stock under the existing ATM agreement, after effectiveness and pursuant to General Instruction I.B.6 of Form S-3.
Since launching the ATM, Hoth has sold 3,919,559 shares for gross proceeds of about $5.5 million. The company cites a public float of approximately $30,968,682, which caps primary offerings at one-third of float over any 12-month period; the new $4,821,200 capacity reflects that limit. Shares trade on Nasdaq as “HOTH,” with a last reported sale price of $1.28 on November 12, 2025.
Hoth Therapeutics (HOTH) filed its Q3 2025 10‑Q, reporting no revenue and a net loss of $4.11 million for the quarter as operating expenses reached $4.08 million. For the nine months, the company recorded a net loss of $9.78 million.
Liquidity remained stable with cash and cash equivalents of $7.85 million as of September 30, 2025. Year‑to‑date, the company used $7.65 million in operating cash and received $8.76 million from financing, including warrant exercises and equity sales. Management states current cash is sufficient to fund operations for at least 12 months from the issuance date of these financial statements, while noting additional capital will be needed to advance programs.
The company maintained an ATM program with total capacity of $7.7 million; approximately $5.5 million of common stock had been sold under the program as of November 11, 2025. Shares outstanding were 15,514,312 as of November 11, 2025. Hoth also reported crypto assets at fair value of $274,695 (BTC, ETH, SOL). Equity activity included the CEO’s 800,000-share restricted stock grant in August.
Hoth Therapeutics (HOTH) filed a Form 8-K to announce that management has prepared investor presentation materials for use on and after October 17, 2025. The materials are included as Exhibit 99.1 and provide summary information about the company’s operations and performance.
The presentation speaks as of the 8-K date, and the company notes it may update the materials but disclaims any obligation to do so. No transactions, financial results, or new guidance are disclosed in this filing.
Robb Knie, CEO and President and a director of Hoth Therapeutics, acquired 800,000 shares of restricted common stock under the company’s Amended and Restated 2022 Equity Incentive Plan; the award vested in full at grant and was issued at $0 per share, bringing his post-award beneficial ownership to 858,131 shares. The next day he sold 310,744 shares at $1.21 per share, reducing his beneficial ownership to 547,387 shares. The Form 4 shows the acquisition was labeled as an issuance that vested on grant and the sale was reported separately. The filing was signed by an attorney-in-fact on behalf of Mr. Knie.
Hoth Therapeutics, Inc. disclosed a material agreement: an Employment Agreement between the company and Robb Knie dated August 22, 2025. The filing is an Form 8-K reporting that the employment contract was furnished as an exhibit and the document is signed by Robb Knie in his capacity as Chief Executive Officer. No financial terms, termination provisions, equity awards, or other compensation details appear in the provided text, and there are no financial statements or earnings information included.